Experimental opioid drug more resistant to abuse, company says

07/25/2013 | Medscape (free registration)

Collegium Pharmaceutical said clinical trial data indicate crushed and snorted multiparticulate capsules of its new, extended-release Oxycodone DETERx do not produce a plasma profile sought by drug abusers. An earlier study of the tamper-resistant experimental drug found similar results with crushing and oral use, the company reported.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN